Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	5.82	5.99	7.81	9.56	15.58
Revenue Growth (YoY)	-2.83%	-23.29%	-18.29%	-38.63%	-
Cost of Revenue	1.63	2.29	1.6	4.05	7.43
Gross Profit	4.19	3.7	6.21	5.51	8.15
Selling, General & Admin	9.26	12.21	15.59	15.67	19.73
Research & Development	2.41	1.74	1.79	0.46	0
Other Operating Expenses	3.28	9.67	6.88	6.66	7.74
Operating Expenses	14.95	23.62	24.26	22.8	27.46
Operating Income	-10.76	-19.92	-18.05	-17.28	-19.31
Interest Expense / Income	0.54	0.6	0.37	3.05	13.84
Other Expense / Income	-3.14	-0.47	-9.43	1.68	-
Pretax Income	-8.16	-20.04	-8.99	-22.01	-33.16
Income Tax	0	0	0	-1.43	-0.65
Net Income	-8.16	-20.04	-8.99	-20.59	-32.51
Preferred Dividends	5.65	0	0	0	0
Net Income Common	-13.81	-20.04	-8.99	-20.59	-32.51
Shares Outstanding (Basic)	2	2	1	1	0
Shares Outstanding (Diluted)	2	2	1	1	0
Shares Change	5.11%	90.11%	103.90%	117.10%	-
EPS (Basic)	-6.35	-9.68	-8.25	-38.50	-132.20
EPS (Diluted)	-6.35	-9.68	-8.25	-38.50	-132.20
Free Cash Flow	-7.63	-12.8	-11.86	-15.31	2.46
Free Cash Flow Per Share	-3.50	-6.18	-10.89	-28.67	10.00
Gross Margin	71.98%	61.79%	79.52%	57.67%	52.32%
Operating Margin	-184.84%	-332.37%	-231.05%	-180.78%	-123.98%
Profit Margin	-237.26%	-334.40%	-115.05%	-215.35%	-208.71%
Free Cash Flow Margin	-130.99%	-213.57%	-151.86%	-160.15%	15.80%
EBITDA	-4.21	-13.73	-1.64	-12.21	-14
EBITDA Margin	-72.34%	-229.06%	-20.94%	-127.72%	-89.84%
Depreciation & Amortization	3.42	5.72	6.98	6.75	5.32
EBIT	-7.63	-19.44	-8.62	-18.96	-19.31
EBIT Margin	-131.00%	-324.46%	-110.33%	-198.36%	-123.98%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).